L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and effectiveness of liquid tumor
infiltrating lymphocytes (L-TIL) combined with tislelizumab as the first-line treatment in
patients with advanced malignant melanoma. This study plan to include stage III or IV
unresectable or metastatic cutaneous or acral malignant melanoma patients, treat with L-TIL 4
cycles with each infusion (3 -10) x10*9/m2 cells, combined with tislelizumab 200mg, iv, Q3W.
It is expected that 30 patients will be enrolled in this study.